Induction of angiogenesis by a type III phosphodiesterase inhibitor, cilostazol, through activation of peroxisome proliferator-activated receptor-γ and cAMP pathways in vascular cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 3, 2016, Pages 545-552

  Sanada, Fumihiro ^a   Kanbara, Yasuhiro ^a   Taniyama, Yoshiaki ^a   Otsu, Rei ^a   Carracedo, Miguel ^a   Ikeda Iwabu, Yuka ^a   Muratsu, Jun ^a   Sugimoto, Ken ^a   Yamamoto, Koichi ^a   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenesis effect; cilostazol; hepatocyte growth factor; intermittent claudication; muscle development; peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPOIETIN 1; CILOSTAZOL; CYCLIC AMP; NEUTRALIZING ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCATTER FACTOR; VASCULOTROPIN; ANGIOGENIC FACTOR; ANGPT1 PROTEIN, MOUSE; HGF PROTEIN, MOUSE; PHOSPHODIESTERASE III INHIBITOR; TETRAZOLE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; LIMB PERFUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE PERFUSION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR SMOOTH MUSCLE CELL; VASCULARIZATION; AGONISTS; ANIMAL; C57BL MOUSE; CAPILLARY; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HINDLIMB; ISCHEMIA; METABOLISM; PATHOPHYSIOLOGY; RAT; SECOND MESSENGER; SKELETAL MUSCLE; SMOOTH MUSCLE CELL; TIME FACTOR;

ANGIOGENESIS INDUCING AGENTS; ANGIOPOIETIN-1; ANIMALS; CAPILLARIES; CELLS, CULTURED; CYCLIC AMP; DISEASE MODELS, ANIMAL; HEPATOCYTE GROWTH FACTOR; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; ISCHEMIA; MICE, INBRED C57BL; MUSCLE, SKELETAL; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHODIESTERASE 3 INHIBITORS; PPAR GAMMA; RATS; SECOND MESSENGER SYSTEMS; TETRAZOLES; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84959577037     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.307011     Document Type: Article

References (29)

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH, Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013 382 1329 1340. doi: 10.1016/S0140-6736(13)61249-0
2. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, Ruckley CV, Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996 25 1172 1181
3. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ, Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991 20 384 392
4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Rutherford RB, TASC II Working Group Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007 26 81 157
5. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D, Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992 326 381 386. doi: 10.1056/NEJM199202063260605
6. Vaartjes I, de Borst GJ, Reitsma JB, de Bruin A, Moll FL, Grobbee DE, Bots ML, Long-Term survival after initial hospital admission for peripheral arterial disease in the lower extremities. BMC Cardiovasc Disord 2009 9 43. doi: 10.1186/1471-2261-9-43
7. O'Donnell ME, Badger SA, Sharif MA, Makar RR, Young IS, Lee B, Soong CV, The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vasc Endovascular Surg 2009 43 132 143. doi: 10.1177/1538574408328586
8. Dawson DL, Cutler BS, Hiatt WR, Hobson RW II, Martin JD, Bortey EB, Forbes WP, Strandness DE Jr, A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000 109 523 530
9. Robless P, Mikhailidis DP, Stansby GP, Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008 1 CD003748
10. Chapman TM, Goa KL, Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003 3 117 138
11. Hashimoto A, Miyakoda G, Hirose Y, Mori T, Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006 189 350 357. doi: 10.1016/j.atherosclerosis.2006.01.022
12. Aoki M, Morishita R, Hayashi S, Jo N, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T, Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001 44 1034 1042. doi: 10.1007/s001250100593
13. Park KH, Jeong MH, Kim JM, The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. Int J Cardiol 2013 168 1853 1858. doi: 10.1016/j.ijcard.2012.12.070
14. Sanada F, Taniyama Y, Azuma J, Yuka II, Kanbara Y, Iwabayashi M, Rakugi H, Morishita R, Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent. Immunol Endocr Metab Agents Med Chem 2014 14 32 39. doi: 10.2174/1871522213999131231105139
15. Melillo G, Serino F, Cirielli C, Capogrossi MC, Gene therapy in peripheral artery disease. Curr Drug Targets Cardiovasc Haematol Disord 2004 4 295 300
16. Morishita R, Higaki J, Hayashi SI, Yo Y, Aoki M, Nakamura S, Moriguchi A, Matsushita H, Matsumoto K, Nakamura T, Ogihara T, Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia 1997 40 1053 1061. doi: 10.1007/s001250050787
17. Yin H, Price F, Rudnicki MA, Satellite cells and the muscle stem cell niche. Physiol Rev 2013 93 23 67. doi: 10.1152/physrev.00043.2011
18. Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW, Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-Activated receptor gamma transcription. J Pharmacol Exp Ther 2009 329 571 579. doi: 10.1124/jpet.108.146456
19. Wang F, Gao L, Gong B, Hu J, Li M, Guan Q, Zhao J, Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Can J Physiol Pharmacol 2008 86 465 471. doi: 10.1139/y08-043
20. Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y, hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-Activated receptor-gamma agonists. J Am Soc Nephrol 2006 17 54 65. doi: 10.1681/ASN.2005030257
21. Hayashi S, Morishita R, Matsushita H, Nakagami H, Taniyama Y, Nakamura T, Aoki M, Yamamoto K, Higaki J, Ogihara T, Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension 2000 35 1 pt 2 237 243
22. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS, Cilostazol for Restenosis Trial (CREST) Investigators Coronary stent restenosis in patients treated with cilostazol. Circulation 2005 112 2826 2832. doi: 10.1161/CIRCULATIONAHA.104.530097
23. Park SY, Lee JH, Kim KY, Kim EK, Yun SJ, Kim CD, Lee WS, Hong KW, Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-Activated receptor-gamma transcription. Atherosclerosis 2008 201 258 265. doi: 10.1016/j.atherosclerosis.2008.02.006
24. Biscetti F, Pecorini G, Straface G, Arena V, Stigliano E, Rutella S, Locatelli F, Angelini F, Ghirlanda G, Flex A, Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol 2013 167 910 916. doi: 10.1016/j.ijcard.2012.03.103
25. Min JK, Lee YM, Kim JH, Kim YM, Kim SW, Lee SY, Gho YS, Oh GT, Kwon YG, Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 2005 96 300 307. doi: 10.1161/01.RES.0000155330.07887.EE
26. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, Isner JM, Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998 97 381 390
27. Kobayashi H, DeBusk LM, Babichev YO, Dumont DJ, Lin PC, Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 2006 108 1260 1266. doi: 10.1182/blood-2005-09-012807
28. Liu Y, Michalopoulos GK, Zarnegar R, Structural and functional characterization of the mouse hepatocyte growth factor gene promoter. J Biol Chem 1994 269 4152 4160
29. Sanada F, Taniyama Y, Iekushi K, Azuma J, Okayama K, Kusunoki H, Koibuchi N, Doi T, Aizawa Y, Morishita R, Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res 2009 105 667 675, 13 p following 675. doi: 10.1161/CIRCRESAHA.109.202713